fls.txt



item1.txt
The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q.
The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, and Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”).
All material intercompany balances and transactions have been eliminated.
2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less.
The Company records revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”).
The following table summarizes the Company’s disaggregation of revenues for the three months ended September 30, 2019 and 2018.
Benchtop Laboratory Equipment sales are comprised primarily of standard benchtop laboratory equipment from its stock to laboratory equipment distributors, or to end users primarily via e-commerce.
Customers either pay by credit card (online sales) or net 30-90, depending on the customer.
The standard warranty is typically comprised of one to two years of parts and labor and is deemed immaterial.
Some contracts call for training and installation, which is considered ancillary and not a material part of the contract.
Due to the size and nature of the instruments, the Company subjects the instruments to an extensive factory acceptance testing process prior to shipment to ensure that they are fully operational once they reach the customer’s site.
Catalyst research instruments are never returned for repairs.
During the year, the Company’s management uses its best judgement to estimate the royalty revenues earned during the period.
Approximately 33% and 25% of total Benchtop Laboratory Equipment sales were derived from the Torbal Scales Division for the three months ended September 30, 2019 and 2018, respectively.
Fair value measurements do not include transaction costs.
Level 1 - Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.
The fair value of the contingent consideration obligations are based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria.


item2.txt
Item 2.
Forward-Looking statements.
Consequently, no forward-looking statement can be guaranteed.
Overview.
Revenues derived from the Bioprocessing Systems Operations which are comprised primarily of net royalties accrued from sublicenses increased by $160,100 (123.9%) to $289,300 for the three months ended September 30, 2019 compared to $129,200 for the three months ended September 30, 2018 due to increased royalties on Europe sales.
As a result of the foregoing, the Company recorded a net loss of $56,200 for the three months ended September 30, 2019 compared to net income of $142,000 for the three months ended September 30, 2018.
Cash and cash equivalents decreased by $342,800 to $1,259,700 as of September 30, 2019 from $1,602,500 as of June 30, 2019.
Net cash used in investing activities was $25,700 for the three months ended September 30, 2019 compared to $4,900 used during the three months ended September 30, 2018 principally due to new capital equipment purchased during the current period by the Benchtop Laboratory Equipment Operations.
The Company has a Demand Line of Credit through December 2019 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently 4.75%.


